Bimagrumab
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly · Phase 2 · Withdrawn · Enrollment 0
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Bimagrumab Dose 1 + Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 2 + Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 1 + Bimagrumab Placebo | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 2 + Bimagrumab Placebo | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 2 + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 1 + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 2 + Tirzepatide Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 1 + Tirzepatide Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab Placebo + Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.